Optimized transcriptional signature for evaluation of MEK/ERK pathway baseline activity and long-term modulations in ovarian cancer

Mikhail S. Chesnokov(University of Minnesota), Ilana Chefetz(Mercer University)

bioRxiv (Cold Spring Harbor Laboratory)

March 23, 2022

10.1101/2022.03.21.485160

Cited by 1

Related Papers

The MEK1/2 Pathway as a Therapeutic Target in High-Grade Serous Ovarian Carcinoma

|Cancers|2021|29

Optimized Transcriptional Signature for Evaluation of MEK/ERK Pathway Baseline Activity and Long-Term Modulations in Ovarian Cancer

|International Journal of Molecular Sciences|2022|11